Related Experiment Video
Updated: Jun 5, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Key Regulatory Elements of the TGFβ-LRRC15 Axis Predict Disease Progression and Immunotherapy Resistance Across
Abstract:
Transforming growth factor-beta (TGFβ) has dual roles in cancer, initially suppressing tumors but later promoting metastasis and immune evasion. Efforts to inhibit TGFβ have been largely unsuccessful due to significant toxicity and indiscriminate immunosuppression. Leucine-rich repeat-containing protein 15 (LRRC15) is a TGFβ-regulated antigen expressed by mesenchymal-derived cancer cells and cancer-associated fibroblasts (CAFs). In preclinical studies, ablation of TGFβ-driven LRRC15+ CAFs increased tumor infiltration of CD8+ T cells. However, the underlying pathobiological mechanisms prompting TGFβ's upregulation of LRRC15 expression are unclear. Using an integrated approach combining functional compound screening with single-cell RNA sequencing, we reveal key genomic features regulating TGFβ's ability to increase LRRC15 expression on cancer cells. Construction of gene regulatory networks converged our analyses on four key genes- MMP2, SPARC, TGF β R2, and WNT5B -central to TGFβ-induced LRRC15 pathobiology. Validation of these genes in cell models and their use in predicting immunotherapy responses highlight their potential in refining immunotherapy strategies and personalizing co-treatment options.
Insights
Transforming growth factor-beta (TGFβ) drives cancer progression by upregulating LRRC15. Identifying key genes like MMP2 and SPARC offers new immunotherapy targets for better cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Transforming growth factor-beta (TGFβ) exhibits complex roles in cancer, initially tumor-suppressive but later promoting metastasis and immune evasion.
- Targeting TGFβ is challenging due to toxicity and broad immunosuppression.
- Leucine-rich repeat-containing protein 15 (LRRC15) is a TGFβ-regulated antigen found on cancer cells and cancer-associated fibroblasts (CAFs), with its precise regulation by TGFβ being unclear.
Purpose of the Study:
- To elucidate the molecular mechanisms by which TGFβ upregulates LRRC15 expression.
- To identify key genomic regulators involved in TGFβ-induced LRRC15 expression.
- To explore the potential of identified genes in predicting immunotherapy response.
Main Methods:
- Integrated functional compound screening and single-cell RNA sequencing.
- Construction of gene regulatory networks.
- Validation in cell models.
Main Results:
- Identified key genomic features regulating TGFβ-induced LRRC15 expression.
- Gene regulatory network analysis pinpointed MMP2, SPARC, TGFβR2, and WNT5B as central regulators.
- Validated the role of these genes in cell models.
Conclusions:
- MMP2, SPARC, TGFβR2, and WNT5B are key mediators of TGFβ-induced LRRC15 pathobiology.
- These genes hold potential for refining immunotherapy strategies.
- Further research may enable personalized co-treatment options for cancer patients.
Related Concept Videos
TGF - β Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Regulation of Angiogenesis and Blood Supply
The Tumor Microenvironment
Abnormal Proliferation

